L-threo-droxidopa

CAS : 23651-95-8

Ref. 3D-FT28252

Informations sur le produit

• Nom: L-threo-droxidopa
• Synonymes: DroxidopaL-threo 3,4-DihydroxyphenylserineL-DOPS
• Marque: Biosynth
• Description: L-threo-droxidopa is a prodrug that is hydrolyzed in the liver to L-3,4-dihydroxyphenylalanine (L-DOPA) and then metabolized by dopamine β-hydroxylase to form dopamine. This drug has been shown to be effective for the treatment of Parkinson's disease. The long-term efficacy of this drug is unknown, but it has been shown to be safe and well tolerated for up to six months. L-threo-droxidopa has also been shown to be effective in lowering systolic blood pressure in patients with mild hypertension. The side effects of this drug include symptoms such as nausea, vomiting, dizziness, headache, and insomnia. However, these side effects are often transient and do not require discontinuation of treatment with this medication. There are no known interactions between L-threo-droxidopa and other drugs or foods. Pharmacological

Propriétés chimiques

• Masse moléculaire: 213.19 g/mol
• Formule: C₉H₁₁NO₅
• Degré de pureté: Min. 95%
• Couleur/Forme: Off-White To Light (Or Pale) Beige Solid
• InChI: InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
• Code InChI: InChIKey=QXWYKJLNLSIPIN-JGVFFNPUSA-N
• SMILES: N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1